2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion

Kasem Nithipatikom, Michael P. Endsley, Marilyn A. Isbell, J R Falck, Yoshiki Iwamoto, Cecilia J. Hillard, William B. Campbell

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Endocannabinoids have been implicated in cancer. Increasing endogenous 2-arachidonoylglycerol (2-AG) by blocking its metabolism inhibits invasion of androgen-independent prostate cancer (PC-3 and DU-145) cells. Noladin ether (a stable 2-AG analog) and exogenous CB1 receptor agonists possess similar effects. Conversely, reducing endogenous 2-AG by inhibiting its synthesis or blocking its binding to CB1 receptors with antagonists increases the cell invasion. 2-AG and noladin ether decrease protein kinase A activity in these cells, indicating coupling of the CB1 receptor to downstream effectors. The results suggest that cellular 2-AG, acting through the CB1 receptor, is an endogenous inhibitor of invasive prostate cancer cells.

Original languageEnglish (US)
Pages (from-to)8826-8830
Number of pages5
JournalCancer Research
Volume64
Issue number24
DOIs
StatePublished - Dec 15 2004

Fingerprint

Cannabinoid Receptor CB1
Androgens
Prostatic Neoplasms
Endocannabinoids
Cyclic AMP-Dependent Protein Kinases
2-arachidonylglycerol
Neoplasms
noladin ether

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nithipatikom, K., Endsley, M. P., Isbell, M. A., Falck, J. R., Iwamoto, Y., Hillard, C. J., & Campbell, W. B. (2004). 2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Research, 64(24), 8826-8830. https://doi.org/10.1158/0008-5472.CAN-04-3136

2-Arachidonoylglycerol : A novel inhibitor of androgen-independent prostate cancer cell invasion. / Nithipatikom, Kasem; Endsley, Michael P.; Isbell, Marilyn A.; Falck, J R; Iwamoto, Yoshiki; Hillard, Cecilia J.; Campbell, William B.

In: Cancer Research, Vol. 64, No. 24, 15.12.2004, p. 8826-8830.

Research output: Contribution to journalArticle

Nithipatikom, K, Endsley, MP, Isbell, MA, Falck, JR, Iwamoto, Y, Hillard, CJ & Campbell, WB 2004, '2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion', Cancer Research, vol. 64, no. 24, pp. 8826-8830. https://doi.org/10.1158/0008-5472.CAN-04-3136
Nithipatikom, Kasem ; Endsley, Michael P. ; Isbell, Marilyn A. ; Falck, J R ; Iwamoto, Yoshiki ; Hillard, Cecilia J. ; Campbell, William B. / 2-Arachidonoylglycerol : A novel inhibitor of androgen-independent prostate cancer cell invasion. In: Cancer Research. 2004 ; Vol. 64, No. 24. pp. 8826-8830.
@article{7ecec9153b4240ea9a8e0a9977fcdbda,
title = "2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion",
abstract = "Endocannabinoids have been implicated in cancer. Increasing endogenous 2-arachidonoylglycerol (2-AG) by blocking its metabolism inhibits invasion of androgen-independent prostate cancer (PC-3 and DU-145) cells. Noladin ether (a stable 2-AG analog) and exogenous CB1 receptor agonists possess similar effects. Conversely, reducing endogenous 2-AG by inhibiting its synthesis or blocking its binding to CB1 receptors with antagonists increases the cell invasion. 2-AG and noladin ether decrease protein kinase A activity in these cells, indicating coupling of the CB1 receptor to downstream effectors. The results suggest that cellular 2-AG, acting through the CB1 receptor, is an endogenous inhibitor of invasive prostate cancer cells.",
author = "Kasem Nithipatikom and Endsley, {Michael P.} and Isbell, {Marilyn A.} and Falck, {J R} and Yoshiki Iwamoto and Hillard, {Cecilia J.} and Campbell, {William B.}",
year = "2004",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-04-3136",
language = "English (US)",
volume = "64",
pages = "8826--8830",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - 2-Arachidonoylglycerol

T2 - A novel inhibitor of androgen-independent prostate cancer cell invasion

AU - Nithipatikom, Kasem

AU - Endsley, Michael P.

AU - Isbell, Marilyn A.

AU - Falck, J R

AU - Iwamoto, Yoshiki

AU - Hillard, Cecilia J.

AU - Campbell, William B.

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Endocannabinoids have been implicated in cancer. Increasing endogenous 2-arachidonoylglycerol (2-AG) by blocking its metabolism inhibits invasion of androgen-independent prostate cancer (PC-3 and DU-145) cells. Noladin ether (a stable 2-AG analog) and exogenous CB1 receptor agonists possess similar effects. Conversely, reducing endogenous 2-AG by inhibiting its synthesis or blocking its binding to CB1 receptors with antagonists increases the cell invasion. 2-AG and noladin ether decrease protein kinase A activity in these cells, indicating coupling of the CB1 receptor to downstream effectors. The results suggest that cellular 2-AG, acting through the CB1 receptor, is an endogenous inhibitor of invasive prostate cancer cells.

AB - Endocannabinoids have been implicated in cancer. Increasing endogenous 2-arachidonoylglycerol (2-AG) by blocking its metabolism inhibits invasion of androgen-independent prostate cancer (PC-3 and DU-145) cells. Noladin ether (a stable 2-AG analog) and exogenous CB1 receptor agonists possess similar effects. Conversely, reducing endogenous 2-AG by inhibiting its synthesis or blocking its binding to CB1 receptors with antagonists increases the cell invasion. 2-AG and noladin ether decrease protein kinase A activity in these cells, indicating coupling of the CB1 receptor to downstream effectors. The results suggest that cellular 2-AG, acting through the CB1 receptor, is an endogenous inhibitor of invasive prostate cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=10844265493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10844265493&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-3136

DO - 10.1158/0008-5472.CAN-04-3136

M3 - Article

C2 - 15604240

AN - SCOPUS:10844265493

VL - 64

SP - 8826

EP - 8830

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -